The relevance of molecular PET parameters in prostate cancer was also highlighted in a recently published consensus statement on PSMA PET/CT-based response assessment, emphasizing the value of semi-quantitative PET parameters, such as standardized uptake value (SUV) and quantification of PSMA-avid tumor burden [31]. The gene discussed is FOLH1; the disease is prostate carcinoma.